Literature DB >> 11498724

Different types of GABA(A) receptors may mediate the anticonflict and response rate-decreasing effects of zaleplon, zolpidem, and midazolam in squirrel monkeys.

C A Paronis1, E D Cox, J M Cook, J Bergman.   

Abstract

RATIONALE: The role of different types of GABA(A) receptors in mediating anticonflict and response rate-decreasing effects of benzodiazepines in primate species is not known.
OBJECTIVE: To examine the behavioral effects of the benzodiazepine-site, GABA(A) agonists zolpidem, zaleplon, and midazolam in the presence of two antagonists, flumazenil and beta-carboline-3-carboxylate-t-butyl ester (beta-CCt) in squirrel monkeys.
METHODS: Two schedules of operant responding were used: (1) a multiple fixed-ratio (FR) schedule of food presentation involving punished and nonpunished behavior, and (2) an FR schedule of stimulus shock-termination.
RESULTS: Midazolam (0.03-1.0 mg/kg), zolpidem (0.1-3.0 mg/kg), and zaleplon (0.1-3.0 mg/kg) increased rates of punished responding and decreased rates of nonpunished responding under the multiple schedule. Pretreatment with flumazenil (0.3-1.0 mg/kg) antagonized the anticonflict and response rate-decreasing effects of all three agonists. Pretreatment with beta-CCt (3-10 mg/kg) antagonized the anticonflict and rate-decreasing effects of midazolam, as well as the rate-decreasing effects of zolpidem and zaleplon. However, beta-CCt did not antagonize the anticonflict effects of zolpidem and zaleplon; instead, these effects of zolpidem and zaleplon were apparently enhanced in the presence of beta-CCt. Under the schedule of stimulus shock-termination, both flumazenil and beta-CCt antagonized zolpidem and zaleplon; however, the effects of beta-CCt were less consistent than the effects of flumazenil.
CONCLUSION: In nonhuman primates, different types of GABAA receptors may mediate the anticonflict and the response rate-decreasing effects of the nonselective GABAA agonist midazolam and the selective GABAA1 agonists zolpidem and zaleplon.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11498724     DOI: 10.1007/s002130100754

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

Review 2.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

3.  Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse.

Authors:  Wenyuan Yin; Samarpan Majumder; Terry Clayton; Steven Petrou; Michael L VanLinn; Ojas A Namjoshi; Chunrong Ma; Brett A Cromer; Bryan L Roth; Donna M Platt; James M Cook
Journal:  Bioorg Med Chem       Date:  2010-09-29       Impact factor: 3.641

4.  Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals.

Authors:  James K Rowlett; John H Kehne; Ken J Sprenger; George D Maynard
Journal:  Psychopharmacology (Berl)       Date:  2010-11-20       Impact factor: 4.530

5.  Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists.

Authors:  Shannon L Gourley; Joseph F Debold; Wenyuan Yin; James Cook; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2004-08-17       Impact factor: 4.530

6.  Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys.

Authors:  Stephanie C Licata; Donna M Platt; James M Cook; Michael L Van Linn; James K Rowlett
Journal:  Psychopharmacology (Berl)       Date:  2008-11-25       Impact factor: 4.530

7.  Pharmacological Properties of DOV 315,090, an ocinaplon metabolite.

Authors:  Dmytro Berezhnoy; Maria C Gravielle; Scott Downing; Emmanuel Kostakis; Anthony S Basile; Phil Skolnick; Terrell T Gibbs; David H Farb
Journal:  BMC Pharmacol       Date:  2008-06-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.